drugset / Trial / NCT00034697

Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)

NCT00034697 ↗

Phase 2 Terminated 24 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

Brain metastases from solid tumors are diagnosed in more than 300,000 patients annually. Nonsmall cell lung cancer accounts for the majority of CNS mets. Treatment with whole brain radiation and steroids will improve neurologic symptoms in about 50% of patients although survival is short. This study will test the safety and efficacy of temozolomide in combination with radiation therapy in the treatment of patients with brain mets form nonsmall cell lung cancer.

Timeline

Start
2001-06-28
Primary completion
2003-01-30
Completion
2003-01-30

Outcome

Outcome not reported

Stopped (Enrollment): “Slow Enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule — —